Posted on November 20, 2015 by Amos Adler
Using digital engagement to increase medication adherence is our novel solution to a complex problem. With non-adherence caused by multiple factors unique to each individual patient, a-one-size-fits-all-solution can’t work and won’t work. Instead, at MEMOTEXT we personalize each patient’s support program. By encouraging patient input, adapting to changes in mood and lifestyle, we can develop a medication adherence and support program that works best.
Posted on October 02, 2015 by Amos Adler
Keywords: #MedXHangover #EmpathyX #MedXorcism, #ActionX
So I’m currently suffering from what’s known as #MedXHangover. Its real, I assure you. Fortunately I don’t have #SyndromeX, a condition associated with attending uncomfortable doctor-patient simulations to simulate uncomfortable doctor-patient interactions.
Posted on June 17, 2015 by Noah Nemoy
On Monday morning, MEMOTEXT’s Founder and President Amos Adler and PerformRx’s Director of Drug Therapy Management Programs & Outcomes Lauren C. Megargell, had the honor to jointly present the results of our HealthNHandSM asthma adherence program to the The Digital Transformation of Patient Care: New Avenues for Pharma Growth Seminar. The seminar was organized by the Consulate General of Canada in New York’s Canadian Technology Accelerator (CTA) Health IT Philadelphia as part of BIO2015.
Attendees can expect to learn about a successful collaborative case study in digital health personalization and adherence engagement
Posted on May 28, 2015 by Noah Nemoy
PerformRx and MEMOTEXT Corp. are pleased to announce their joint presentation on HealthNHandSM at the Consulate General of Canada’s The Digital Transformation of Patient Care: New Avenues for Pharma Growth Seminar in Philadelphia, on June 15th. HealthNHand is being cited as successful case study, in both digital health personalization and adherence engagement.
MEMOTEXT Validates the Balanced Adherence Metric (BAM)
Posted on May 28, 2015 by Noah Nemoy
Finding ways to accurately measure medication adherence can be difficult. Currently, most metrics use pharmacy claims data to measure an individual’s adherence. Many academics and professionals use measures like Proportion of Days Covered (PDC) or Medication Possession Ratio (MPR). But while these measures have several advantages, they don’t account for other adherence factors, such as delay to refill and medication persistence. To solve the problem, MEMOTEXT developed the Balanced Adherence Metric (BAM). BAM amalgamates the four most common adherence measures, providing a more accurate and holistic metric.
Posted on May 5, 2015 by Noah Nemoy
On April. 30th 2015, I had the privilege of being part of the MEMOTEXT delegation to AppsForHealth in Hamilton. AppsForHealth was hosted by Hamilton’s Mohawk College, and is one of the largest digital health conferences in Ontario. Our Founder and President Amos Adler was honoured with a speaking invitation.
Posted on March 11, 2015 by Noah Nemoy
This March 8-15, is World Glaucoma Week. Launched 6 years ago by the World Glaucoma Association and The World Glaucoma Patient Association, events are being held across the world to raise awareness about Glaucoma. Afflicting 9 million people, Glaucoma is the world’s leading cause of irreversible blindness. Due to its slow progression, 50% of patients in the developed world and 90% in the developing world are untreated. While Glaucoma is currently incurable, with early detection and treatment, its progression can be halted.
Posted on February 26, 2015 by Noah Nemoy
On February 25, 2014, MEMOTEXT Founder and President Amos Adler was invited to give a guest lecture at the University of Toronto. This honor was fresh off the heels of MEMOTEXT’s participation at the University of Toronto’s Rotman School of Management’s IT in Healthcare Speaker Series earlier this month. The lecture was presented to Prof. Joseph Cafazzo’s Health Informatics class.
Posted on February 2, 2015 by Bill Simpson
I am not a medical historian, but I would bet that if you asked one, they would identify the synthesis of Aspirin in 1897 as one of most significant moments in modern medicine. With its pain-relieving, anti-inflammatory and anti-platelet (blood thinning) properties packaged within a single tablet, Aspirin provided a safe, effective and easy treatment for a wide range of illnesses. Even today, it is listed on the World Health Organization’s List of Essential Medicines and is taken daily by millions of people for the prevention of heart attacks and strokes. Its synthesis (and the pharmaceutical revolution it helped to user in) has no doubt helped to increase our lifespan and bring about a higher quality of life.